HALIFAX, July 11, 2014 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR)
announced today that Markus Meile has been appointed as the Company's
Chief Financial Officer. Effective immediately, Mr. Meile replaces
Jelle Kuypers who has chosen to depart the Company. Mr. Meile's
proficiency in international finance, in addition to his experience in
the medical device industry, makes him a valued member of the Company's
executive leadership team as it drives MedMira's strategic initiatives
forward. Mr. Kuypers will assist with the transfer of the Company's
financial leadership and day-to-day functions to Mr. Meile and his team
during a defined transition period.
Mr. Meile has served as a member of MedMira's Board of Directors since
2010, was previously a member of its Audit Committee and, most
recently, led the Company's business development activities as Senior
Director, International Markets. Effectively immediately, Mr. Meile
will step down from the Board to move into his new role as Chief
"On behalf of the Board and the management team, I would like to thank
Mr. Kuypers for his contributions to MedMira and the support provided
to the Company during this transition period. Mr. Kuypers has helped
MedMira move to an enhanced financial foundation upon which our future
success will be built," said Hermes Chan, CEO, MedMira Inc.
Prior to joining MedMira, Mr. Meile worked with a number of financial
institutions in Switzerland, England, and Hong Kong. Mr. Meile holds a
BSc from Royal Holloway University of London and has studied business
management, strategic planning, investment and accounting at business
school in Zurich. Previously, Mr. Meile worked in the medical device
industry in Africa, Asia Pacific, and Europe. Mr. Meile will combine
his financial expertise with his broad range of international business
knowledge to build financial and corporate strategies supporting
MedMira's continuing growth and increasing shareholder value.
Mr. Meile's appointment as MedMira's Chief Financial Officer is subject
to final approval of the TSX Venture Exchange.
MedMira is a leading developer and manufacturer of vertical flow rapid
diagnostics. The Company's tests provide hospitals, labs, clinics and
individuals with instant diagnosis for diseases such as HIV and
hepatitis C in just three easy steps. The Company's tests are sold
under the Reveal®, Multiplo™ and Miriad™ brands in global markets. Based on its patented
Rapid Vertical Flow Technology™, MedMira's rapid HIV test is the first
one in the world to achieve regulatory approvals in Canada, the United
States, China and the European Union. MedMira's corporate offices and
manufacturing facilities are located in Halifax, Nova Scotia, Canada.
For more information visit medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
approval and launch of new products, future growth, and new business
opportunities. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MedMira Inc.
For further information:
Andrea Young, Corporate Communications